|
β
|
Transmission rate/week |
0.4167 (based on 30–50% prevalence [58]) |
0.0893 (based on 30% prevalence [41]) |
Varies by age, see [2]
|
|
τ
|
Treatment rate/week |
0.02 (lower end of childhood antibiotic prescribing range [59]) |
0.0003, 0.0017, 0.0033 (10, 50, and 100% respectively of MSSA-active antibiotic prescriptions per person per week in the U.S., weighted by ages in 2010 census data [33]) |
40% of infections are treated |
|
u
|
Clearance rate/week |
0.25 (duration of 30 days [60], [61]) |
0.01, 0.02, 0.04 (duration of 175–700 days [56], [57]) |
2.1 (duration of 3.3 days) |
|
p
|
Proportion of population that is vaccinated |
0.8 (well below U.S. childhood vaccination rates [62]) |
Range: 0–1
|
0.4
|
|
VE
|
Vaccine efficacy (overall) |
Range: 0–1
|
n/a |
59% (effects on infectiousness neglected) |
|
θ or VER
|
Additional vaccine efficacy against resistant strain (θ, S. pneumo, Flu) or total vaccine efficacy against resistant strain only (VER, S. aureus) |
Range: 0–1
|
Range: 0–1
|
Range: 0–20% |
|
ψ
|
Fitness cost |
Range: 0, 0.08 (estimated based on in vitro data [36]) |
0.02, 0.04, 0.08 (range of fitness costs in field strains [34]) |
0
|
